Covalent drugs have emerged as a groundbreaking modality for improving the affinity, potency, and duration of action of molecularly targeted inhibitors. Prof. ... Read more

A major challenge in developing viral-based therapies, such as gene therapies, CAR-T cell immunotherapy, and oncolytic virotherapy, is that the most efficient vectors and viruses are not specific, preventing their direct administration to the patient. Prof. ... Read more

Enveloped viruses pose significant health risks and lack effective treatments. Inhibiting viral membrane fusion, a crucial step in infection, holds promise for antiviral drug development. Dr. ... Read more

Chimeric Antigen Receptor (CAR)-T Cell Therapy is a personalized treatment for cancer in which the patient's T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. ... Read more

This technology provides a method to identify the full landscape of proteins that are actively being degraded by the proteasome, offering a way to identify novel targets in various biological conditions and contexts. ... Read more